Project Grant R21CA287351
Award Date
12/1/24
Completion Date
11/30/26
Dollars Obligated
$212K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This federal Project Grant award of $221,456.00 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) aims to develop and optimize a novel approach for enriching microbes from clinical cancer samples to enable deep metaproteomic analysis. The research team, led by the Regents of the University of Minnesota, will pursue two specific aims: 1) Optimize and evaluate the CS-BONCAT (bio-orthogonal non-canonical amino acid tagging) method in samples of known...
This Project Grant award of $352,275.00 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) aims to develop a novel agent called MITOMET to target mitochondria in lung cancer cells with co-occurring KRAS and LKB1 mutations. The 5-year project, which began on January 1, 2025, seeks to assess the safety and efficacy of MITOMET in suppressing the malignant progression of lung tumors, determine its ability to modulate the tumor immune microenvironment, and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $105,189 to the Regents of the University of Minnesota to advance research on inhibiting the structural dynamics of the APOBEC3A (A3A) and APOBEC3B (A3B) enzymes. The key objectives are to: Elucidate the structures of A3A and A3B when bound to viral inhibitors, such as ribonucleotide reductases from Macacine G-herpesvirus 11 and Kaposi Sarcoma-associated Herpesvirus, using...
The National Cancer Institute (NCI) awarded a $386,700 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the Regents of the University of Minnesota. The grant, titled "Preclinical Development and Validation of Targeted Mass Spectrometry Assays for Serous Ovarian Cancer Diagnosis", will fund research to develop and validate novel multiplexed protein biomarker assays that can differentiate serous ovarian cancer patients from healthy individuals. The...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $1,373,308 to the University of Pittsburgh to conduct research on the role of acetylcarnitine metabolism in ovarian cancer chemoresistance. The project aims to: 1) quantitatively and mechanistically map the acetylcarnitine-dependent histone acetylation axis and its contribution to homologous recombination-mediated DNA repair, and 2) investigate whether interventions that...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $150,271 to the University of Maryland Baltimore County (UMBC) to investigate the role of the protein kinase ADCK5 in ovarian cancer. The 2-year project, which began on September 20, 2023, aims to gain fundamental insights into the mechanisms underlying ovarian cancer, the most lethal gynecologic malignancy in the United States. The research seeks to identify potential new...
This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $159,803 to the Regents of the University of Michigan to incorporate emerging genomic, transcriptomic, epigenomic, and proteomic technologies for the analysis of advanced, rare, and pediatric cancers. The project aims to translate these new analytical approaches into clinically actionable information through the development of reportable test results in the...
This federal Project Grant award of $412,429 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to investigate novel approaches to overcome drug resistance in high-grade serous ovarian cancer (HGSOC). The award aims to demonstrate that combining the drug clofarabine with either a PARP inhibitor or an ATR inhibitor can sensitize CCNE1-driven tumors to these therapies by inducing replication stress through nuclear translocation of the protein cathepsin...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) will provide $136,412 to the Regents of the University of Michigan to conduct research on defining and interrupting metabolic crosstalk in the glioblastoma (GBM) microenvironment. The primary goals are to: 1) determine mechanistically how metabolite exchange between normal brain cells and GBM cancer cells promotes tumor growth and therapy resistance; 2) investigate the impact of disrupting...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $394,532 to the Regents of the University of Minnesota to conduct research on using the amino acid transporter LAT1 as a novel therapeutic target for colorectal cancer. The research aims to evaluate the impact of LAT1 inhibition on tumor growth and immune cell infiltration, as well as assess the efficacy of the LAT1-specific inhibitor JPH203 in combination with immune checkpoint...